Cancer Chemotherapy and Pharmacology

, Volume 71, Issue 5, pp 1191–1199

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

  • Ruth Plummer
  • Paul Lorigan
  • Neil Steven
  • Lucy Scott
  • Mark R. Middleton
  • Richard H. Wilson
  • Evan Mulligan
  • Nicola Curtin
  • Diane Wang
  • Raz Dewji
  • Antonello Abbattista
  • Jorge Gallo
  • Hilary Calvert
Original Article

DOI: 10.1007/s00280-013-2113-1

Cite this article as:
Plummer, R., Lorigan, P., Steven, N. et al. Cancer Chemother Pharmacol (2013) 71: 1191. doi:10.1007/s00280-013-2113-1
  • 1.2k Downloads

Abstract

Purpose

poly(ADP ribose) polymerase inhibition has been shown to potentiate the cytotoxicity of DNA damaging agents. A phase I study of rucaparib and temozolomide showed that full-dose temozolomide could be given during PARP inhibition. We report the results of a phase II study of intravenous rucaparib 12 mg/m2 and oral temozolomide 200 mg/m2 on days 1–5 every 28 days in patients with advanced metastatic melanoma.

Methods

Patients with chemotherapy naïve measurable metastatic melanoma, performance status ≤2 and good end-organ function were recruited. Treatment was given until progression. A two stage phase II design was used, with response rate the primary endpoint. Population pharmacokinetics and pharmacodynamics were also explored.

Results

Forty-six patients were recruited with 37 patients receiving at least 2 cycles and 17 patients at least 6 cycles. Myelosuppression occurred with 25 patients (54 %) requiring a 25 % dose reduction in temozolomide. The response rate was 17.4 %, median time to progression 3.5 months, median overall survival 9.9 months, and 36 % of patients were progression-free at 6 months.

Conclusions

This study showed that temozolomide (150–200 mg/m2/day) can safely be given with a PARP inhibitory dose of rucaparib, increasing progression-free survival over historical controls in metastatic melanoma patients.

Keywords

PARP DNA repair Melanoma Chemopotentiation Phase II 

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Ruth Plummer
    • 1
  • Paul Lorigan
    • 2
  • Neil Steven
    • 3
  • Lucy Scott
    • 4
  • Mark R. Middleton
    • 5
  • Richard H. Wilson
    • 6
  • Evan Mulligan
    • 1
  • Nicola Curtin
    • 1
  • Diane Wang
    • 7
  • Raz Dewji
    • 8
  • Antonello Abbattista
    • 9
  • Jorge Gallo
    • 9
  • Hilary Calvert
    • 1
  1. 1.Institute for Cancer Research, Paul O’Gorman BuildingNewcastle UniversityNewcastle upon TyneUK
  2. 2.Christie HospitalManchesterUK
  3. 3.Institute for Cancer StudiesBirminghamUK
  4. 4.Beatson West of Scotland Oncology CentreGlasgowUK
  5. 5.Department of OncologyUniversity of Oxford, Churchill HospitalOxfordUK
  6. 6.Centre for Cancer Research and Cell BiologyQueen’s UniversityBelfastUK
  7. 7.Pfizer GRDLa JollaUSA
  8. 8.Pfizer GRDSandwichUK
  9. 9.Pfizer GRDMilanItaly

Personalised recommendations